U.S. markets open in 7 hours 15 minutes
  • S&P Futures

    3,886.00
    +18.50 (+0.48%)
     
  • Dow Futures

    31,496.00
    +138.00 (+0.44%)
     
  • Nasdaq Futures

    13,148.00
    +92.75 (+0.71%)
     
  • Russell 2000 Futures

    2,255.90
    +26.80 (+1.20%)
     
  • Crude Oil

    60.05
    +0.30 (+0.50%)
     
  • Gold

    1,730.20
    -3.40 (-0.20%)
     
  • Silver

    26.72
    -0.16 (-0.61%)
     
  • EUR/USD

    1.2088
    0.0000 (-0.00%)
     
  • 10-Yr Bond

    1.4150
    0.0000 (0.00%)
     
  • Vix

    24.10
    +0.75 (+3.21%)
     
  • GBP/USD

    1.3958
    +0.0001 (+0.01%)
     
  • USD/JPY

    106.8650
    +0.1550 (+0.15%)
     
  • BTC-USD

    49,612.62
    +1,038.01 (+2.14%)
     
  • CMC Crypto 200

    996.85
    +8.76 (+0.89%)
     
  • FTSE 100

    6,613.75
    +25.22 (+0.38%)
     
  • Nikkei 225

    29,559.10
    +150.93 (+0.51%)
     

Japara Healthcare's (ASX:JHC) Stock Price Has Reduced 74% In The Past Five Years

  • Oops!
    Something went wrong.
    Please try again later.
Simply Wall St
·3 min read
  • Oops!
    Something went wrong.
    Please try again later.

While not a mind-blowing move, it is good to see that the Japara Healthcare Limited (ASX:JHC) share price has gained 13% in the last three months. But that doesn't change the fact that the returns over the last half decade have been disappointing. In fact, the share price has declined rather badly, down some 74% in that time. So we're not so sure if the recent bounce should be celebrated. We'd err towards caution given the long term under-performance.

View our latest analysis for Japara Healthcare

While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time.

In the last half decade Japara Healthcare saw its share price fall as its EPS declined below zero. At present it's hard to make valid comparisons between EPS and the share price. However, we can say we'd expect to see a falling share price in this scenario.

You can see below how EPS has changed over time (discover the exact values by clicking on the image).

earnings-per-share-growth
earnings-per-share-growth

Before buying or selling a stock, we always recommend a close examination of historic growth trends, available here.

What about the Total Shareholder Return (TSR)?

We'd be remiss not to mention the difference between Japara Healthcare's total shareholder return (TSR) and its share price return. The TSR attempts to capture the value of dividends (as if they were reinvested) as well as any spin-offs or discounted capital raisings offered to shareholders. Dividends have been really beneficial for Japara Healthcare shareholders, and that cash payout explains why its total shareholder loss of 67%, over the last 5 years, isn't as bad as the share price return.

A Different Perspective

Japara Healthcare shareholders are down 14% for the year, but the market itself is up 2.7%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Unfortunately, longer term shareholders are suffering worse, given the loss of 11% doled out over the last five years. We'd need to see some sustained improvements in the key metrics before we could muster much enthusiasm. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. To that end, you should learn about the 2 warning signs we've spotted with Japara Healthcare (including 1 which doesn't sit too well with us) .

For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on AU exchanges.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.